News
Valbiotis erhält Patent für seinen Wirkstoff TOTUM•63 in China, einem Markt mit großem Potential bei der Vorbeugung von Typ-2-Diabetes und Stoffwechselkrankheiten
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies’ COVID-19 vaccine
Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data from clinical studies evaluating Rubraca and/or lucitanib and one abstract on real world data of PARP
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005957/en/
Please replace the release dated May 19, 2021 with
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Quantum Genomics Announces the Publication of New Scientific Article in Biomedecine et Pharmacotherapy which further strengthen its Phase III development plan in difficult to treat and resistant hypertension
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to
Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, eligible for the PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement
Clovis Oncology Announces At-The-Market Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell, from time
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare &
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract
QIAGEN gibt Gründung eines Scientific Advisory Boards und die Tagesordnung der Hauptversammlung im Juni 2021 bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Gründung eines Scientific Advisory Boards sowie Neuerungen im Aufsichtsrat im Vorfeld der für Juni 2021 geplanten
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the creation of a Scientific Advisory Board as well as updates on the Supervisory Board ahead of the Annual General Meeting
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Company’s Board
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences:
-
RBC
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending March 31, 2021 and
IMV Inc. to Present at Two Upcoming Investor Conferences
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV’s executive management team will be participating in two upcoming investor conferences.
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational